title: XRCC1 Arg399Gln, Arg194Trp, and Arg280His polymorphisms in esophageal cancer risk: a meta-analysis.
abstract: BACKGROUND
  The X-ray repair cross-complementation group 1 (XRCC1) protein plays an important role in base excision repair.
  
  
  OBJECTIVE
  To elucidate the role of XRCC1 Arg399Gln, Arg194Trp and Arg280His genotypes in esophageal cancer risk, all available studies were considered in the present meta-analysis.
  
  
  METHODS
  Eligible studies were identified by searching several electronic databases for relevant reports published before June 2012.
  
  
  RESULTS
  According to the inclusion criteria and exclusion criteria, a total of 21 eligible studies were included in the pooled analyses. Among the 21 studies, 18 focused on Arg399Gln polymorphism, 11 described the Arg194Trp, and 4 articles investigated on Arg280His. Our analysis suggested that there was no evidence of significant association between XRCC1 Arg399Gln polymorphism and esophageal cancer risk in any genetic model. In the stratified analysis by ethnicity for Arg399Gln polymorphism and esophageal cancer, the results showed that Arg399Gln polymorphism was not associated with esophageal cancer risk. Only 4 studies analyzed the relationship between XRCC1 Arg280His polymorphism and the risk of esophageal cancer. The Arg/His and His/His genotypes were not significantly associated with increased risk of EC. A similar negative association was maintained in dominant and recessive models. However, for XRCC1 Arg194Trp polymorphism, our study showed individuals carrying the variant genotype Trp/Trp had a significant increased risk of esophageal cancer (OR = 1.295, 95 % CI 1.053-1.591, P = 0.014). In addition, increased associations were found in recessive model (OR = 1.332, 95 % CI 1.093-1.624, P = 0.005).
  
  
  CONCLUSIONS
  Our meta-analysis suggested that Arg194Trp Trp allele might act as a risk allele in its association with esophageal cancer.
authors.affiliation: Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Li
authors.forename: Yan
authors.initials: Y
authors.lastname: Deng
authors.forename: Jian-Peng
authors.initials: JP
authors.lastname: You
authors.forename: Zhi-Ping
authors.initials: ZP
authors.lastname: Chen
authors.forename: Qi-Liu
authors.initials: QL
authors.lastname: Peng
authors.forename: Xia-Mei
authors.initials: XM
authors.lastname: Huang
authors.forename: Qing-Hua
authors.initials: QH
authors.lastname: Lu
authors.forename: Xiu-Li
authors.initials: XL
authors.lastname: Huang
authors.forename: Jin-Min
authors.initials: JM
authors.lastname: Zhao
authors.forename: Xue
authors.initials: X
authors.lastname: Qin
mesh_terms: D000230:Adenocarcinoma / Q000208:ethnology / Q000235:genetics*; D044466:Asian People; D002294:Carcinoma, Squamous Cell / Q000208:ethnology / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics*; D004938:Esophageal Neoplasms / Q000208:ethnology / Q000235:genetics*; D005819:Genetic Markers; D006801:Humans; D015233:Models, Statistical; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D044465:White People; D000076105:X-ray Repair Cross Complementing Protein 1
chemical_list: D004268:DNA-Binding Proteins; D005819:Genetic Markers; D000076105:X-ray Repair Cross Complementing Protein 1; C000619371:XRCC1 protein, human
references.citation: Int J Cancer. 1994 Jul 15;58(2):192-6
references.pmid: 8026880
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):353-8
references.pmid: 16492928
references.citation: Science. 2001 Feb 16;291(5507):1284-9
references.pmid: 11181991
references.citation: J Natl Cancer Inst. 2005 Jan 19;97(2):142-6
references.pmid: 15657344
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Int J Cancer. 1994 Jul 15;58(2):197-202
references.pmid: 8026881
references.citation: J Thorac Oncol. 2010 Nov;5(11):1741-7
references.pmid: 20975374
references.citation: Carcinogenesis. 2000 May;21(5):965-71
references.pmid: 10783319
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52
references.pmid: 12163328
references.citation: Genes Dev. 1999 Apr 1;13(7):768-85
references.pmid: 10197977
references.citation: Int J Cancer. 2005 Jan 20;113(3):475-82
references.pmid: 15455377
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Cancer Res. 1998 Feb 15;58(4):604-8
references.pmid: 9485007
references.citation: Prostate Cancer Prostatic Dis. 2011 Sep;14(3):225-31
references.pmid: 21647176
references.citation: Cancer Res. 2004 Jun 15;64(12):4378-84
references.pmid: 15205355
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Int J Cancer. 2001 Jul 20;95(4):240-6
references.pmid: 11400117
references.citation: Int J Cancer. 2000 Jul 15;87(2):289-94
references.pmid: 10861489
references.citation: Carcinogenesis. 1992 Aug;13(8):1331-5
references.pmid: 1499084
references.citation: Bull Cancer. 2009 Oct;96(10):E61-5
references.pmid: 19762325
references.citation: Int J Cancer. 2008 Jul 1;123(1):174-80
references.pmid: 18386788
references.citation: Cancer Res. 1999 Jun 1;59(11):2557-61
references.pmid: 10363972
references.citation: Int J Cancer. 2002 Aug 10;100(5):600-5
references.pmid: 12124811
references.citation: Br J Cancer. 2004 Apr 5;90(7):1402-6
references.pmid: 15054463
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):125-31
references.pmid: 11219769
references.citation: Int J Cancer. 2003 Sep 20;106(5):771-83
references.pmid: 12866039
references.citation: Am J Epidemiol. 2005 Nov 15;162(10):925-42
references.pmid: 16221808
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):736-9
references.pmid: 18349297
references.citation: Cancer Causes Control. 2008 Dec;19(10):1077-83
references.pmid: 18478337
references.citation: Mutat Res. 2000 Feb 16;459(1):1-18
references.pmid: 10677679
references.citation: Cancer Lett. 2004 Dec 28;216(2):157-64
references.pmid: 15533591
references.citation: Lung Cancer. 2001 Dec;34(3):333-9
references.pmid: 11714530
references.citation: N Engl J Med. 1999 Mar 18;340(11):825-31
references.pmid: 10080844
references.citation: Int J Cancer. 2009 Sep 1;125(5):1102-9
references.pmid: 19444915
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62
references.pmid: 11588131
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Mol Cell Biol. 1998 Jun;18(6):3563-71
references.pmid: 9584196
references.citation: Mol Biol Rep. 2011 Oct;38(7):4565-73
references.pmid: 21499756
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1810-8
references.pmid: 16030121
references.citation: Cancer Genet Cytogenet. 2007 Jun;175(2):91-7
references.pmid: 17556064
references.citation: Cancer Detect Prev. 2004;28(3):194-9
references.pmid: 15225899
references.citation: Mol Cell Biol. 1994 Jan;14(1):68-76
references.pmid: 8264637
references.citation: Carcinogenesis. 2005 Sep;26(9):1536-41
references.pmid: 15878910
references.citation: Biomed Environ Sci. 2011 Jun;24(3):268-74
references.pmid: 21784313
references.citation: Carcinogenesis. 2007 Jun;28(6):1254-8
references.pmid: 17264068
references.citation: Carcinogenesis. 2006 Sep;27(9):1835-41
references.pmid: 16571649
references.citation: Cancer. 2006 Jun 1;106(11):2345-54
references.pmid: 16639733
references.citation: EMBO J. 1996 Dec 2;15(23):6662-70
references.pmid: 8978692
references.citation: Biochimie. 1999 Jan-Feb;81(1-2):39-44
references.pmid: 10214908